|
1
|
Caldwell S and Argo C: The natural history
of non-alcoholic fatty liver disease. Dig Dis. 28:162–168.
2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Portillo-Sanchez P, Bril F, Maximos M,
Lomonaco R, Bermacki D, Orsak B, Subbarayan S, Webb A, Hecht J and
Cusi K: High prevalence of nonalcoholic fatty liver disease in
patients with type 2 diabetes mellitus and normal plasma
aminotransferase levels. J Clin Endocrinol Metab. 100:2231–2238.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Remus Popa A, Fratila O, Rus M, Corb Aron
RA, Mihai Vesa C, Pantis C, Diaconu CC, Bratu O, Bungau S and
Nemeth S: Risk factors for adiposity in the urban population and
influence on the prevalence of overweight and obesity. Exp Ther
Med. 20:129–133. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Vesa CM, Popa L, Popa AR, Rus M, Zaha AA,
Bungau S, Tit DM, Corb Aron RA and Zaha DC: Current data regarding
the relationship between type 2 diabetes mellitus and
cardiovascular risk factors. Diagnostics (Basel).
10(314)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhou Y and Rui L: Leptin signaling and
leptin resistance. Front Med. 7:207–222. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ernst MB, Wunderlich CM, Hess S, Paehler
M, Mesaros A, Koralov SB, Kleinridders A, Husch A, Münzberg H,
Hampel B, et al: Enhanced Stat3 activation in POMC neurons provokes
negative feedback inhibition of leptin and insulin signaling in
obesity. J Neurosci. 29:11582–11593. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
American Diabetes Association. 2.
Classification and diagnosis of diabetes: Standards of medical care
in diabetes-2020. Diabetes Care. 43 (Suppl 1):S14–S31.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Margetic S, Gazzola C, Pegg GG and Hill
RA: Leptin: A review of its peripheral actions and interactions.
Int J Obes Relat Metab Disord. 26:1407–1433. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Myers MG Jr, Leibel RL, Seeley RJ and
Schwartz MW: Obesity and leptin resistance: Distinguishing cause
from effect. Trends Endocrinol Metab. 21:643–651. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ikejima K, Okumura K, Lang T, Honda H, Abe
W, Yamashina S, Enomoto N, Takei Y and Sato N: The role of leptin
in progression of non-alcoholic fatty liver disease. Hepatol Res.
33:151–154. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Moonishaa TM, Nanda SK, Shamraj M, Sivaa
R, Sivakumar P and Ravichandran K: Evaluation of leptin as a marker
of insulin resistance in type 2 diabetes mellitus. Int J Appl Basic
Med Res. 7:176–180. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tiwari-Heckler S, Gan-Schreier H, Stremmel
W, Chamulitrat W and Pathil A: Circulating phospholipid patterns in
NAFLD patients associated with a combination of metabolic risk
factors. Nutrients. 10(649)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lustig RH, Sen S, Soberman JE and
Velasquez-Mieyer PA: Obesity, leptin resistance, and the effects of
insulin reduction. Int J Obes Relat Metab Disord. 28:1344–1348.
2004.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Paz-Filho G, Mastronardi C, Wong ML and
Licinio J: Leptin therapy, insulin sensitivity, and glucose
homeostasis. Indian J Endocrinol Metab. 16 (Suppl 3):S549–S555.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Popa AR, Bungau S, Vesa CM, Bondar AC,
Pantis C, Maghiar O, Dimulescu IA, Nistor-Cseppento DC and Rus M:
Evaluating the efficacy of the treatment with benfotiamine and
alpha-lipoic acid in distal symmetric painful diabetic
polyneuropathy. Rev Chim. 70:3108–3114. 2019.
|
|
16
|
Moisi IM, Rus M, Bungau S, Zaha CD,
Uivarosan D, Fratila O, Tit DM, Endres L, Nistor-Cseppento DC and
Popescu MI: Acute coronary syndromes in chronic kidney disease:
Clinical and therapeutic characteristics. Medicina (Kaunas).
56(118)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Misra VL, Khashab M and Chalasani N:
Nonalcoholic fatty liver disease and cardiovascular risk. Curr
Gastroenterol Rep. 11:50–55. 2009.
|
|
18
|
Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM
and Park SK: Clinical association between non-alcoholic fatty liver
disease and the development of hypertension. J Gastroenterol
Hepatol. 29:1926–1931. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Adolph TE, Grander C, Grabherr F and Tilg
H: Adipokines and non-alcoholic fatty liver disease, multiple
interactions. Int J Mol Sci. 18(1649)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lee Y, Kwon EY and Choi MS: Dietary
isoliquiritigenin at a low dose ameliorates insulin resistance and
NAFLD in diet-induced obesity in C57BL/6J mice. Int J Mol Sci.
19(3281)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tacelli M, Celsa C, Magro B, Giannetti A,
Pennisi G, Spatola F and Petta S: Drugs in NAFLD: The
accomplishment of two goals at once? Pharmaceuticals (Basel).
11(121)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sharma D, Wang J, Fu PP, Sharma S,
Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA and
Saxena NK: Adiponectin antagonizes the oncogenic actions of leptin
in hepatocellular carcinogenesis. Hepatology. 52:1713–22.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Diaconu C, Salmen T, Gaman MA, Bratu OG,
Mischianu D, Marcu RD, Suceveanu AI, Costache RS and Pantea Stoian
A: SGLT2 inhibition in patients with type 2 diabetes and
cardiovascular diseases: Which are the benefits? Rom J Mil Med.
122:16–21. 2019.
|
